Standard BioTools Inc
LAB
Company Profile
Business description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Contact
2 Tower Place
Suite 2000
South San FranciscoCA94080
USAT: +1 650 266-6000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
818
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
stocks
Alphabet: Gemini momentum and possible Meta TPU deal underscore AI capability
We think Alphabet is exceptionally well positioned in everything AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.70 | 5.40 | -0.06% |
| CAC 40 | 8,096.43 | 70.63 | 0.88% |
| DAX 40 | 23,726.22 | 261.59 | 1.11% |
| Dow JONES (US) | 47,427.12 | 314.67 | 0.67% |
| FTSE 100 | 9,691.58 | 82.05 | 0.85% |
| HKSE | 25,999.72 | 71.64 | 0.28% |
| NASDAQ | 23,214.69 | 189.10 | 0.82% |
| Nikkei 225 | 50,050.18 | 491.11 | 0.99% |
| NZX 50 Index | 13,440.48 | 121.53 | -0.90% |
| S&P 500 | 6,812.61 | 46.73 | 0.69% |
| S&P/ASX 200 | 8,610.70 | 4.20 | -0.05% |
| SSE Composite Index | 3,883.01 | 18.83 | 0.49% |